Ana Maria Arance
Grupo de investigación
- Genómica traslacional y terapias dirigidas en tumores sólidos Accredited researcher (R3A)
Publicaciones destacadas
-
Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East
Autores:Referencia: International Journal Of Cancer 2021. -
Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy
Autores:Referencia: Journal Of Diabetes Investigation 2021. -
Molecular Markers and Targets in Melanoma
Autores:Referencia: Cells 2021. -
Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma
Autores:Referencia: Annals Of Oncology 2021. -
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
Autores:Referencia: European Journal Of Cancer 2021. -
Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence
Autores:Referencia: Acta Dermato-Venereologica 2021. -
Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication
Autores:Referencia: Immunotherapy 2021. -
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Autores:Referencia: Bmc Cancer 2021. -
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
Autores:Referencia: Cancers 2021. -
Cobimetinib plus atezolizumab in BRAF<sup>V600</sup> wild-type melanoma: primary results from the randomized phase 3 IMspire170 study
Autores:Referencia: Annals Of Oncology 2021.